Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Speedier lab test could curb superbug threat in ICU pneumonia

NCT ID NCT02897466

Diagnosis Sponsor: Assistance Publique - Hôpitaux de Paris Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 12, 2026 · Last updated Aug 13, 2026 · Updated 1 time

Summary

This trial tests a faster method of identifying which antibiotics can kill the bacteria causing ventilator-associated pneumonia (VAP) in intensive care patients. The new approach, called direct antimicrobial susceptibility testing (DAST), gives results about a day earlier than standard testing. The goal is to see if this quicker information helps doctors choose effective antibiotics without relying on broad-spectrum drugs like carbapenems, potentially improving treatment and reducing antibiotic resistance.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Direct antimicrobial susceptibility testing (DAST) performed on respiratory samples, combined with mass spectrometry for bacterial identification.
What this could lead to
If effective, this rapid testing method could help doctors choose the right antibiotics sooner, potentially improving outcomes and reducing the spread of drug-resistant bacteria.
What could go wrong
The test may not always be accurate or feasible, and the trial is relatively small. Faster results might not translate into better patient outcomes or reduced antibiotic resistance in practice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

91 people

The number who actually took part.

Started

Dec 2017

Finished

Aug 2020

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults (18 years or older) * Need for mechanical ventilation expected for at least 5 days at any time during the ICU stay (including if the intubation was performed before the ICU admission) * VAP suspected and clinical respiratory samples with GNB at direct smear examination * At least one condition with a risk factor of multidrug resistant infection: 1. Previous use of antimicrobials (at least 2 days in the past 7 days) 2. Risk of colonization or infection with MDR or XDR bacteria within 3 months * Written informed consent has to be obtained from the patients or a surrogate. The patient or his surrogate can withdraw from the study at any time. Exclusion Criteria: * Pregnant or lactating women * VAP suspected and respiratory samples without GNB at direct smear examination * VAP that occurred without neither previous antimicrobial exposure in the past 5 days or neither risk of MDR colonization * Samples send to the lab during night and weekend in center if respiratory samples are not performed during this period * Active therapeutic limitation * Known allergy to antibiotics * Social welfare unavailable

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Ventilator associated pneumonia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Pneumonia, Ventilator-Associated

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Ventilator associated pneumonia

Contacts and locations

Locations

  • Bichat Hospital

    Paris, 75018, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.